BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cannabis Science Inc. Appoints Harvard University Law School Graduate Chad S. Johnson, Esq. as a Member of the Company's Board of Directors and as General Counsel


11/13/2012 9:41:22 AM

COLORADO SPRINGS, Colo., Nov. 13, 2012 /PRNewswire/ -- Cannabis Science Inc., (OTC:CBIS) announced today the appointment of Harvard Law School Graduate Chad S. Johnson, Esq., as a member of the company's Board of Directors and as General Counsel, adding significant expertise to Cannabis Science's management team in business development, legal & regulatory compliance, and for-profit and non-profit partnerships.

About Chad S. Johnson, Esq.

Mr. Johnson, a native of Emporia, Kansas, began his professional career in 1992 after graduating from Harvard College and Harvard Law School.  Following a federal judicial clerkship, Mr. Johnson joined the law firm Skadden Arps Slate Meagher & Flom LLP, where he practiced for several years in federal and state financial institution regulatory law with a focus on mergers and acquisitions, serving such clients as Citigroup, Sumitomo Bank, and Travelers.  He also performed substantial pro bono work for national LGBT and HIV and AIDS organizations while at Skadden.  In 2000, Mr. Johnson left his firm to serve as the Deputy Director of Business Leader Outreach and Deputy Director of Gay and Lesbian Issues for the Gore/Lieberman campaign, after which he served as Executive Director of the National Stonewall Democrats, the only national LGBT gay Democrats organization in the nation.  In addition to other legal and business endeavors, Mr. Johnson co-founded the World AIDS Institute, a non-profit organization dedicated to document and preserve the global history of AIDS, to inspire action today to improve the lives of people living with HIV and AIDS (and their family, friends, and communities), and to strengthen the spectrum of innovative initiatives to find a cure, and more recently in 2012 co-founded with Timothy Ray Brown (the Berlin Patient) and David Purdy, the only organization with a sole mission of finding an HIV cure: the Timothy Ray Brown Foundation of the World AIDS Institute. 

"We are honored to announce Chad Johnson's appointment both as a member of our Board of Directors and as General Counsel of Cannabis Science.  Mr. Johnson's proven background in corporate governance, corporate merger and acquisition regulation, constitutional and civil rights law, and political activism will add layers of intellectual wealth and valuable experience to our growing team. His appointment furthers our ties with the World AIDS Institute, of which Chad is a Co-Founder.  We are proud to foster creative synergies between a nonprofit, formed to promote HIV awareness and education and to advance efforts to find an HIV cure with a public company medicinalizing cannabis-based extracts that are proving effective in treating HIV-related illnesses' stated Dr. Robert Melamede, President & CEO, Cannabis Science Inc.

About CS-TATI-1

Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About CS-S/BCC-1

Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has begun preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

About Cannabis Science, Inc.

Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in new drug development, medicinal characterization, and clinical research to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the transdermal delivery of CS-TATI-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Recent presentations at AIDS 2012 and The International Conference on Antiviral Research have provoked federal research interest in the development of CS-TATI-1.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science, Inc.
President and CEO
Dr. Robert J. Melamede, 888-889-0888
info@cannabisscience.com
or
VP of Investor Relations
Robert Kane, 561-234-6929
rkane@cannabisscience.com
www.cannabisscience.com

SOURCE Cannabis Science, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->